As traditional anticancer
treatments fail to significantly improve
the prognoses, exploration of therapeutic modalities is urgently needed.
Herein, a biomimetic magnetosome is constructed to favor the ferroptosis/immunomodulation
synergism in cancer. This magnetosome is composed of an Fe3O4 magnetic nanocluster (NC) as the core and pre-engineered
leukocyte membranes as the cloak, wherein TGF-β inhibitor (Ti)
can be loaded inside the membrane and PD-1 antibody (Pa) can be anchored
on the membrane surface. After intravenous injection, the membrane
camouflage results in long circulation, and the NC core with magnetization
and superparamagnetism enables magnetic targeting with magnetic resonance
imaging (MRI) guidance. Once inside the tumor, Pa and Ti cooperate
to create an immunogenic microenvironment, which increases the amount
of H2O2 in polarized M1 macrophages and thus
promotes the Fenton reaction with Fe ions released from NCs. The generated
hydroxyl radicals (•OH) subsequently induce lethal ferroptosis
to tumor cells, and the exposed tumor antigen, in turn, improves the
microenvironment immunogenicity. The synergism of immunomodulation
and ferroptosis in such a cyclical manner therefore leads to potent
therapeutic effects with few abnormalities, which supports the engineered
magnetosomes as a promising combination modality for anticancer therapy.
Enzymatic catalysis in living cells enables the in-situ detection of cellular metabolites in single cells, which could contribute to early diagnosis of diseases. In this study, enzyme is packaged in amorphous metal-organic frameworks (MOFs) via a one-pot co-precipitation process under ambient conditions, exhibiting 5–20 times higher apparent activity than when the enzyme is encapsulated in corresponding crystalline MOFs. Molecular simulation and cryo-electron tomography (Cryo-ET) combined with other techniques demonstrate that the mesopores generated in this disordered and fuzzy structure endow the packaged enzyme with high enzyme activity. The highly active glucose oxidase delivered by the amorphous MOF nanoparticles allows the noninvasive and facile measurement of glucose in single living cells, which can be used to distinguish between cancerous and normal cells.
Adoptive T-cell transfer for cancer therapy relies on both effective ex vivo T-cell expansion and in vivo targeting performance. One promising but challenging method for accomplishing this purpose is to construct multifunctional artificial antigen-presenting cells (aAPCs). We herein developed biomimetic magnetosomes as versatile aAPCs, wherein magnetic nanoclusters were coated with azide-engineered leucocyte membranes and then decorated with T-cell stimuli through copper-free click chemistry. These nano aAPCs not only exhibited high performance for antigen-specific cytotoxic T-cell (CTL) expansion and stimulation but also visually and effectively guided reinfused CTLs to tumor tissues through magnetic resonance imaging and magnetic control. The persisting T cells were able to delay tumor growth in a murine lymphoma model, while the systemic toxicity was not notable. These results together demonstrated the excellent potential of this "one-but-all" aAPC platform for T-cell-based anticancer immunotherapy.
A novel biomimetic immuno-magnetosome (IMS) is developed by coating a leukocyte membrane (decorated with anti-epithelial cell-adhesion molecule antibody) on a magnetic nanocluster. In addition to the good stability and magnetic controllability, the IMS also exhibits satisfactory binding avidity to circulating tumor cells but stealth property to leukocytes. As a result, rare tumor cells can be effectively enriched with undetectable leukocyte background.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.